Investor Relations

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.

NASDAQLPCN
FormDescriptionDateFormat
4Statement of changes in beneficial ownership of securitiesDec 8, 2016View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesDec 8, 2016View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesDec 8, 2016View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJun 17, 2016View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJun 17, 2016View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJun 17, 2016View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJun 17, 2016View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 7, 2016View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 7, 2016View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 7, 2016View HTMLDownload DOCDownload PDF